Table 1 Clinical characteristics of the population studied
| Â | Background metformin | Background sulfonylurea | ||
|---|---|---|---|---|
| Â | + rosiglitazone | + sulfonylurea | + rosiglitazone | + metformin |
Participants (n) | 176 | 165 | 160 | 167 |
Age (yr) | 57 ± 8 | 57 ± 8 | 60 ± 8 | 58 ± 8 |
Male (n (%)) | 80 (45) | 86 (52) | 83 (52) | 77 (46) |
Europid (n (%)) | 175 (> 99) | 165 (100) | 160 (100) | 167 (100) |
Body weight (kg) | 92 ± 17 | 94 ± 16 | 86 ± 13 | 84 ± 16 |
BMI (kg/m2) | 33 ± 5 | 32 ± 5 | 31 ± 4 | 30 ± 5 |
Time from diabetes diagnosis (yr) | 5.7 ± 3.8 | 5.9 ± 3.6 | 7.7 ± 5.1 | 7.1 ± 5.1 |
HbA1c (%) | 7.8 ± 0.6 | 7.8 ± 0.8 | 7.9 ± 0.7 | 8.0 ± 0.8 |
Fasting plasma glucose (mmol/l) | 9.2 ± 2.1 | 9.7 ± 2.3 | 10.0 ± 2.4 | 10.2 ± 2.4 |
Homeostasis model assessment %S (%) | 68 (42, 106) | 64 (42, 108) | 64 (47, 88) | 63 (42, 93) |
Hypertension* (n (%)) | 145 (82) | 138 (84) | 139 (87) | 141 (84) |
Treated with antihypertensive drugs | 119 (68) | 112 (68) | 104 (65) | 114 (68) |
Ambulatory systolic BP (mmHg) | Â | Â | Â | Â |
   24-hour | 132 ± 14 | 134 ± 16 | 132 ± 13 | 132 ± 14 |
   Day-time | 136 ± 14 | 138 ± 15 | 135 ± 13 | 136 ± 14 |
   Night-time | 126 ± 15 | 128 ± 18 | 126 ± 14 | 127 ± 15 |
Ambulatory diastolic BP (mmHg) | Â | Â | Â | Â |
   24-hour | 78 ± 8 | 78 ± 9 | 76 ± 8 | 76 ± 8 |
   Day-time | 81 ± 8 | 82 ± 10 | 79 ± 8 | 79 ± 8 |
   Night-time | 72 ± 9 | 73 ± 10 | 71 ± 9 | 71 ± 9 |
Ambulatory heart rate (beat/min) | Â | Â | Â | Â |
   24-hour | 76 ± 10 | 75 ± 9 | 74 ± 11 | 75 ± 10 |
   Day-time | 81 ± 11 | 80 ± 10 | 79 ± 12 | 78 ± 11 |
   Night-time | 70 ± 9 | 69 ± 9 | 68 ± 10 | 69 ± 9 |